ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1719

NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model

Yen Po Tsao1, Fang-Yu Tseng2, Ming-Han Chen3 and SZUTING CHEN2, 1Taipei Veterans General Hospital, Taipei, Taiwan, 2National Yang Ming Chao Tung University, Taipei, Taiwan, 3Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan

Meeting: ACR Convergence 2022

Keywords: Animal Model, Lupus nephritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Animal Models Poster

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune disease that interferon (IFN) signature involved in the progress. NLRP12 (NOD-like receptor family (NLR) pyrin domain containing 12) is a pyrin containing NLR protein that we had linked its new biological function to the cross-regulation of Toll like receptor (TLRs) and Rig-I like receptor (RIG-I) pathways. NLPR12 acts as an innate immune check-point in regulating type I IFNs expression. Since NLRP12 may participate in the pathogenesis of lupus, its role in lupus nephritis remained unknown.

Methods: Wild type C57BL/6J (The Jackson Laboratory) and Nlrp12-/- mice in 12 -week-old age were injected intraperitoneally with a single dose of 500 μl of pristane (2,6,10,14-tetramethylpentadecane, TMPD), and samples were collected from 1st, 3rd, and 5th months after injection. Serum were collected for evaluation autoantibodies, complement, and renal functions. Kidneys were checked with histological and immune cells evaluation.

Results: The pristane-treated Nlrp12-/- mice had significantly amount of an anti-dsDNA autoreactive antibody in serum than that in WT mice during whole period (1st, 3rd and 5th month, P < 0.001, 0.02, 0.04 respectively). The extent of IgG deposition in the glomerulus are very different in WT and Nlrp12-/- mice (1st, 3rd and 5th month, P < 0.001). Expansion of IgG deposition continued till 5th month. At the following 3rd and 5th month, amount of serum C3 was gradually decreased and Nlrp12-/- mice exhibited the moderately lower serum C3 level compared to the WT mice. The pristane treated Nlrp12-/- mice had greater tubular IgG deposition than WT mice during the whole period. The histologic analysis revealed the morphological change of tubules, dilatation of tubules and loss of TBM integrity in the 3rd month after pristane injection in Nlrp12-/- mice, which were less severe in WT mice. In the pristane model, we found the glomerular ICs deposition occurred significantly from 3rd and rise gradually to 5th month and this aligned with CD11b+ and Ly6C+ cells recruitment suggesting the inflammatory responses in glomerulus. The periodic acid–Schiff (PAS) and H&E stain reveals the enlargement of glomerulus from 3rd to 5th month. Progressive expansion of PAS staining was observed in WT mice, with more profound mesangial proliferation, enlarged tuft with surrounding tubule epithelium effacement and dilation in Nlrp12-/- mice. The histologic scoring revealed Nlrp12-/- had more severe glomeruli damage associating with enlarged glomerulus area from 3rd to 5th month post pristane injection (P = 0.003 and 0.004). Similarly, the increase of mesangial index represents the mesangial expansion with their elevated serum creatinine, especially in Nlrp12-/- mice of 5th month supporting an evidence of deterioration of kidney function.

Conclusion: The deposition of IgG/ICs in the glomerulus causes a series of inflammatory reaction. In pristane lupus-like model, NLRP12 deficiency promotes the prolonged inflammatory response and enhanced systemic autoantibodies production which facilitate the structural damage among the tubules and glomeruli that cause kidney damage.


Disclosures: Y. Tsao, None; F. Tseng, None; M. Chen, None; S. CHEN, None.

To cite this abstract in AMA style:

Tsao Y, Tseng F, Chen M, CHEN S. NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/nlrp12-deficiency-mice-present-severer-lupus-nephritis-in-a-pristane-induced-lupus-like-model/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nlrp12-deficiency-mice-present-severer-lupus-nephritis-in-a-pristane-induced-lupus-like-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology